Live feed12:00:00·962dPRReleasevia QuantisnowXilio Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, in Late Line Patients with Advanced Solid TumorsByQuantisnow·Wall Street's wire, on your screen.XLO· Xilio Therapeutics Inc.Health Care
